PT0253 / PAQ Therapeutics - LARVOL DELTA

PBI-381, a development candidate PROTAC for KRasG12D solid tumors (AACR 2026) - "At present, ASP3082 (Astellas Pharma) and PT0253 (PAQ Therapeutics) are the only two KRasG12D PROTAC degraders that have entered clinical trials.Polymed Biopharmaceuticals has generated a series of potent and selective PROTAC molecules targeting the KRasG12D mutant protein. In head-to-head comparison studies using xenograft models, PBI-381 also exhibited significantly higher anti-tumor activity than ASP3082. IND-enabling activities on PBI-381 are underway to progress the compound further towards the clinic."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

PAQ Therapeutics…announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader (PRNewswire) - "The Series B extension builds on PAQ's previously announced Series B financing, with participation from existing as well as new investors, and further strengthens the company's balance sheet to advance multiple clinical programs. Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ's KRAS G12D degrader, as well as the clinical advancement of PT0511....The Phase 1 study is a first-in-human, open-label, dose-escalation trial evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PT0511 in patients with advanced solid tumors harboring KRAS alterations."

Financing • Trial status • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer